『Proactive - Interviews for investors』のカバーアート

Proactive - Interviews for investors

Proactive - Interviews for investors

著者： Proactive
無料で聴く

概要
 Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business. 個人ファイナンス 政治・政府 毎時 経済学
エピソード
  • Silver Range identifies new drill targets at East Goldfield property in Nevada

    Silver Range identifies new drill targets at East Goldfield property in Nevada
    2026/11/11
    Silver Range Resources CEO Mike Power joined Steve Darling from Proactive to discuss results from a three-dimensional induced polarization (3D-IP) and resistivity survey at the company’s East Goldfield Property in Nye County, Nevada. The survey identified a large zone of elevated chargeability associated with surface lithocap and ledge-style epithermal high-sulphidation mineralization. The inverted chargeability and resistivity data are considered reliable to depths of approximately 250 to 500 metres below surface, depending on the geometry of the source bodies. Conducted across the western portion of the property, the survey outlined an anomaly interpreted to define the limits of a high-sulphidation mineralized system, or cell. The anomaly encompasses the historic Tom Keane Mine as well as a drill target identified through historical drilling in the immediate mine area. Power told Proactive that the company's primary target lies northwest of the Tom Keane Mine and its associated historical drill target. The area is characterized by faulted and intensely alunite-altered pyroclastic rocks of the Milltown Andesite. The geological setting is significant because the Milltown Andesite hosts high-grade high-sulphidation gold mineralization in the Goldfield Main district, located approximately eight kilometres west of East Goldfield along a shared structural corridor. Silver Range plans to use the survey results to advance the target toward drilling. The company intends to design and obtain permits for a drill program to test the core target. #proactiveinvestors #silverrangeresources #tsxv #sng #mining #GoldExploration #Nevada #EastGoldfield #Goldfield #GoldMining #InducedPolarization #Geophysics #MineralExploration #Mining
    続きを読む 一部表示
    5 分
  • Medicus Pharma shares rationale as CD228V becomes lead development priority

    Medicus Pharma shares rationale as CD228V becomes lead development priority
    2026/11/11
    Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug conjugate licensed from Pfizer. For the three months ended September 30, 2026, Medicus reported a net loss of $15.2 million, or $11.64 per share, compared with a loss of $16 million, or $56.18 per share, in the same period last year. Medicus ended the quarter with $13.1 million in cash, cash equivalents and restricted cash, including $5 million in unrestricted cash and cash equivalents. Bokhari said the third quarter marked a transformation for Medicus into a precision oncology-focused biotechnology company, with CD228V now its principal development priority. Medicus holds an exclusive worldwide licence to develop, manufacture and commercialize CD228V through a co-development agreement with Pfizer, which has provided $2 million in development funding. The company is targeting initial clinical proof-of-concept in patients with relapsed, refractory or immunotherapy-resistant melanoma. The program is supported by an existing US investigational new drug application and a first-in-human Phase 1 study. Medicus believes CD228V could potentially achieve an objective response rate above 30% in melanoma, although that target has yet to be demonstrated in clinical trials. Pfizer also has the option to fund all or part of development costs beginning with the first pivotal trial. Medicus is also advancing plans to separate its SkinJect business through a proposed business combination with a special purpose acquisition company. Meanwhile, for Teverelix, the company has submitted a proposed seamless Phase 2b/3 clinical trial protocol to the US Food and Drug Administration for advanced prostate cancer. The study is designed to enrol approximately 608 patients, subject to meeting predefined criteria to proceed. Rather than fund the Teverelix study itself, Medicus intends to pursue an out-licensing agreement or another strategic partnership to advance the program. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CD228V #PrecisionOncology #Biotechnology #CancerResearch #Melanoma #Pfizer #SkinJect #Teverelix #ClinicalTrials #Pharma
    続きを読む 一部表示
    9 分
  • Meren CEO outlines Nigerian drilling push after strong quarter

    Meren CEO outlines Nigerian drilling push after strong quarter
    2026/11/12
    Meren Energy Inc (TSX:MER, STO:MER, OTCQX:MRNFF) CEO Dr Oliver Quinn spoke with Proactive's Stephen Gunnion about strong third-quarter financial results, renewed drilling activity in Nigeria and plans to accelerate operations during 2027. Meren reported quarterly EBITDA of more than $110 million and free cash flow of $59 million, with higher commodity prices supporting performance. Cumulative EBITDA for the first nine months also exceeded the company's full-year 2025 total, despite slightly lower production. Quinn explained that Meren's return to drilling follows an 18-month pause, which allowed its joint venture to assess new subsurface data and complete engineering work. A rig is now testing exploration potential before moving on to infill wells aimed at supporting near-term production. Further activity is planned at another Nigerian field, with two rigs expected to be operating during 2027. The CEO also discussed opportunities to appraise discovered resources and connect them to existing infrastructure, alongside the company's disciplined approach to capital allocation. Meren reduced net debt by approximately $27 million during the quarter, maintained net debt to EBITDA at around 0.5 times and reported liquidity above $300 million. Quinn outlined how the company intends to balance investment in production growth with financial resilience and the potential for rapid returns from infill drilling and well workovers. For more oil and gas company interviews, energy market updates and investor insights, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy #Meren #OilAndGas #NigeriaOil #OliverQuinn #OilProduction #NigeriaEnergy #OilExploration #OilDrilling #EnergyStocks #EBITDA #FreeCashFlow #EnergyInvestment #OilAndGasInvesting #ProactiveInvestors
    続きを読む 一部表示
    5 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません